Ferraton

Quick links to important sections

Ferraton

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ferraton

Quick Facts: Ferraton (Ferrous Fumarate)

Property Description
Active Ingredient (API) Ferrous Fumarate
Form Oral tablet or capsule
Pharmacological Class Antianemic Agent / Essential Mineral Supplement
Primary Therapeutic Use Treatment and prevention of Iron Deficiency Anemia
Differentiation High Elemental Iron Content

What type of medicine is Ferraton and what is its main use?

Ferraton (containing Ferrous Fumarate) is an antianemic agent belonging to the class of essential mineral supplements, primarily prescribed to prevent and treat iron deficiency anemia. Its core function is to supply the body with the necessary elemental iron for vital physiological processes.

Iron is an essential nutrient critical for forming hemoglobin, which is responsible for oxygen transport in the blood. The effectiveness of oral ferrous salts in treating iron deficiency anemia is clinically supported, confirming their primary role in restoring iron stores. Ferrous Fumarate is often favored due to its high concentration of elemental iron compared to other common iron salts.


What is Ferraton made of, and what is its form?

Ferraton is typically a synthetic small-molecule compound containing Ferrous Fumarate as its Active Pharmaceutical Ingredient (API). This compound is a chemically engineered iron salt, and it is commonly manufactured as an oral solid dosage form, such as a film-coated tablet or capsule.

Unlike the simple mineral, the Ferrous Fumarate salt is clinically acknowledged for its stability and predictable absorption profile, which is crucial for maximizing the amount of iron the body can utilize. It is used globally in many popular, highly bioavailable iron supplement brands.


How does Ferraton help address Iron Deficiency?

Ferraton acts as a direct substrate by providing the necessary elemental iron to the bone marrow, enabling the synthesis of functional hemoglobin. By correcting the iron deficit, the medication supports the body's natural production of red blood cells (erythropoiesis), which is impaired during deficiency. This role is strictly about supplying the vital raw material required for the body's internal processes to function correctly.

What side effects are possible with Ferraton?

Possible Side Effects and Safety Information

The safety profile of Ferraton (Ferrous Fumarate) is characterized by a high incidence of gastrointestinal events and crucial safety constraints related to acute toxicity and specific underlying health conditions, as documented in official regulatory sources.

Common and Expected Adverse Reactions

Adverse effects are most frequently classified as Common in regulatory documents and involve the Gastrointestinal Disorders system. These effects may include nausea, vomiting, abdominal pain, constipation, and diarrhea.

A specific, non-clinical change that is officially documented and expected is the appearance of black or dark-colored stools, which results from unabsorbed iron and does not typically indicate a serious issue.

Adverse Reaction Frequency System-Organ Class Examples
Common Gastrointestinal Disorders Nausea, Constipation, Diarrhea
Rare Immune System Disorders Hypersensitivity Reactions

Serious Adverse Reactions and Safety Constraints

The most significant safety concern noted across regulatory labels is the risk of Acute Iron Poisoning (Toxicity). Accidental overdose of iron-containing products is specifically identified as a leading cause of fatal poisoning in children under 6 years, a warning emphasized by the FDA.

Safety constraints restrict the use of Ferraton in specific patient populations. It is formally contraindicated in individuals with conditions of excessive iron storage, such as haemochromatosis or haemosiderosis, as well as in patients suffering from anemias that are not caused by iron deficiency.

Common gastrointestinal side effects are often reported to be more frequent at the start of treatment or during periods of dose escalation.

Overdose and Emergency Response

The official documentation for Ferraton (Ferrous Fumarate) describes overdose as a severe, multi-system toxicological event resulting from the corrosive and systemic effects of elemental iron.

Officially Documented Overdose Manifestations and Outcomes

Overdose Manifestations (Initial) Severe Outcomes (Life-Threatening)
Vomiting (which may be bloody/hematemesis), severe abdominal pain, and bloody diarrhea are common initial signs. Shock, low blood pressure, and acute liver failure are documented consequences of systemic toxicity.
Other presentations include drowsiness, lethargy, signs of hypoperfusion (e.g., clammy skin), and rapid heart rate. Potential for seizures, coma, and fatality is recognized in regulatory warnings, alongside metabolic acidosis.

Accidental overdose of iron-containing products is cited in official labeling as a leading cause of fatal poisoning in children under 6 years of age. Regulatory guidance mandates that if an overdose is suspected, immediate medical attention must be sought. Individuals must contact a Poison Control Center or emergency medical services immediately, especially if the person has collapsed, had a seizure, or is unresponsive. Management procedures documented in official prescribing information include the use of specific chelating agents, such as Deferoxamine, alongside symptomatic and supportive treatment to stabilize vital signs and manage systemic complications.

Therapeutic Uses of Ferraton

What Ferraton Treats: Main Uses and Benefits

Ferraton is commonly used to help address iron deficiency anemia. This medication may assist with easing the overall symptom load. It is applied across domains where additional symptomatic support is needed.

It is relevant for managing symptom clusters that interfere with daily comfort, such as chronic tiredness, generalized weakness, and lack of stamina. It is commonly used in contexts involving conditions associated with acute or disruptive episodes, including heavy menstrual bleeding or supportive care during pregnancy.

Quick Fact: Area of Focus: Physical Strain

The medication supports general well-being during symptomatic phases and may help patients cope more steadily with symptom fluctuations.

“This medication is applied in addressing symptoms that create noticeable physiological strain.”

Eligibility and Restrictions for Use

Eligibility Scope

Category Official Regulatory Statement
Populations for whom use is allowed Adults and adolescents with a diagnosed iron deficiency or iron deficiency anemia.
Populations for whom use is not recommended Young children (under 12 years) for tablet formulations; liquid forms may be advised instead.
Populations for whom use is contraindicated Patients with conditions causing iron overload (e.g., hemochromatosis, hemosiderosis), or active gastrointestinal disease (e.g., active peptic ulcer, ulcerative colitis, regional enteritis).
Age-related eligibility rules Use is strictly restricted in children under 6 years due to the severe risk of fatal accidental poisoning. Use in the elderly is generally permitted under standard adult guidelines.
Condition-specific eligibility rules Contraindicated in anaemias other than iron deficiency anaemia (e.g., those due to iron non-utilisation like Thalassaemia) and for patients undergoing repeated blood transfusions.
Pregnancy and lactation eligibility status Permitted for use during pregnancy and breastfeeding when a clinical diagnosis of iron deficiency is established.
Eligibility-related restrictions Caution is required for use in patients with a history of stomach or duodenal ulcers or those who have had major stomach surgery (e.g., post-gastrectomy).

Eligibility Classifications (High-Level)

Classification Details
Eligibility severity classification Contraindicated (absolute prohibition), Caution/Conditional Use, and Permitted (allowed under standard labeled conditions).
Eligibility-context constraints Prohibitions focus on preventing the risk of iron accumulation/toxicity and avoiding gastrointestinal complications.

Connection to the overall eligibility profile:

Regulatory documents strictly define who can and cannot use the medicine based on two primary risks: the possibility of iron accumulation in individuals with existing iron storage diseases or certain anaemias, and the potential for gastrointestinal irritation in those with active ulcers or colitis. Eligibility is established for adults and adolescents with diagnosed iron deficiency, but it is entirely prohibited for individuals falling under the formal contraindication categories listed in the official labeling.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Ferrous Fumarate (Ferraton) exhibits pharmacokinetic interaction patterns that primarily involve chelation, which reduces the systemic exposure of both the iron and co-administered agents. Regulatory documentation formally classifies these interactions, requiring adherence to specific administration rules.

Interactions Affecting Exposure and Bioavailability

Interacting Substance Category Official Interaction Outcome
Tetracyclines & Quinolones Reduced absorption of both the antibiotic and the iron component.
Levothyroxine (Thyroid Hormone) Reduced absorption of levothyroxine, potentially reducing its efficacy.
Biphosphonates & Penicillamine Reduced absorption and subsequent systemic exposure of the co-administered drug.
Antacids, Food, Milk Reduced oral iron absorption, decreasing its overall bioavailability.
Ascorbic Acid (Vitamin C) Officially documented to enhance the absorption of iron.

Administration-Timing Requirements

The most significant interaction constraint is the mandatory requirement to separate the time of administration of oral iron from medicines such as antacids, certain antibiotics, and thyroid hormones. This timing separation is necessary to mitigate the reduced bioavailability caused by chelation.

Restrictions on Use

Ferrous Fumarate is formally contraindicated in conditions defined by iron overload, specifically Hemosiderosis and Hemochromatosis. For iron products containing folic acid, co-administration is restricted in untreated Pernicious Anemia.

Mechanism of Action

How Ferraton Works: Mechanistic Principles

Ferraton acts as a chelator by directly engaging and binding to excess ferric iron ( Fe^3+) ions present in the bloodstream and stored within peripheral tissues. The drug's molecular structure enables it to form a stable, six-coordinate bond with the metal ion, yielding a stable, inert coordination complex.

This molecular interaction represents the critical first step in inactivating the iron's biological reactivity, preventing the unbound iron from participating in pro-oxidative reactions. Following complex formation, the mechanism shifts to systemic clearance. The newly formed, water-soluble iron-drug complex is processed by the body and efficiently removed via the reticuloendothelial system and through major excretory pathways (primarily the kidneys and bile). This physiological process results in a verifiable reduction in the total mass of chelatable iron within the body's internal environment.

Dosage and Administration Information

How to Use Ferraton

Ferraton (Ferrous Fumarate) is administered exclusively via the oral route as a tablet, capsule, or liquid solution. Usage instructions are designed to maximize the absorption of elemental iron while ensuring correct dosage duration to replenish body stores.


Administration Principles

Principle Official Guidelines
Dosing Pattern Daily doses equivalent to 100 mg to 200 mg elemental iron are typically used for the treatment of anemia, often administered in divided doses (e.g., two to three times daily) or, in some protocols, once daily.
Timing & Food The medicine is ideally taken on an empty stomach to optimize absorption; however, it may be taken with or immediately after food to reduce gastrointestinal discomfort.
Duration of Use Treatment continues for a prolonged period, typically 3 to 6 months after the patient's hemoglobin levels have normalized. This extended course is necessary to adequately refill the body’s iron stores.
Form Handling Tablets and capsules must be swallowed whole with water and should not be crushed, chewed, or sucked, which prevents potential local irritation and tooth staining.

Contextual Constraints

Standard guidelines emphasize the need to separate Ferrous Fumarate from certain foods and medications. It must not be taken with milk, coffee, or tea, as these inhibit iron absorption. Furthermore, administration must be separated by at least two hours from certain medications like levothyroxine and some antibiotics to prevent drug binding. Dosing for specific populations, such as pediatric patients, is determined based on body weight to ensure safety and efficacy.

Recent Clinical Evidence

Research evidence / Overview of Studies for Ferraton

This section summarizes the structure of the official research evidence for the use of Ferraton (Ferrous Fumarate) in iron deficiency, describing the types of studies conducted, the outcomes they measured, and what remains uncertain according to scientific literature. Research provides context but not individual predictions; findings describe group patterns, not personal outcomes.


Evidence for Use in Iron Deficiency Anemia (IDA)

The evidence base for Ferraton in treating Iron Deficiency Anemia (IDA) relies on numerous Randomized Controlled Trials (RCTs) and comprehensive Systematic Reviews. These studies primarily examine hematologic biomarkers, such as quantifying changes in Hemoglobin (Hb) concentration and monitoring levels of Serum Ferritin. Studies monitored measured changes in biomarkers, consistent with the objective of monitoring iron status.

The main research limitation frames relate to patient adherence: data show patterns related to gastrointestinal symptoms; poor compliance and a lower total dose received were monitored in some study settings. Research is ongoing to establish an optimal dosing regimen that balances tolerability and iron absorption.


Evidence for Special Populations and Emerging Research

Ferraton's role was studied for management of iron needs during pregnancy through RCTs focused on monitoring maternal Hb and ferritin levels. Large reviews reported varied findings: research monitored for changes in anemia risk in the mother; however, the certainty remains low for some of the specific fetal and neonatal outcomes that were measured.

In the context of Non-Anemic Iron Deficiency (NAID), smaller trials have explored whether the administration of oral iron was associated with biomarker shifts and patterns of self-reported improvement in scores on fatigue scales. Research indicates that the data for these groups remain insufficient, and sample sizes were modest compared to IDA trials.


What is Still Uncertain About Ferraton Research

Research points to several areas where certainty remains low and research is ongoing. A key research area for limitation is the study of tolerability and iron absorption: the optimal dosing regimen that minimizes gastrointestinal discomfort while supporting iron absorption is not fully established. Furthermore, long-term effects are not fully established regarding the sustained maintenance of iron levels after treatment is stopped, especially in populations with chronic iron loss.

Key Studies & References

  1. WHO guideline: Daily iron and folic acid supplementation in pregnant women

Frequently Asked Questions (FAQ)

Common questions about Ferraton (FAQ)


Q: Why did my doctor prescribe Ferraton instead of another drug?

Regulatory documents state that Ferraton's active ingredient, Ferrous Fumarate, has a high concentration of elemental iron compared to other iron salts. Official product information also notes that it may be less irritant to the gastro-intestinal tract than certain other common iron salts. These differences may be considered by a healthcare provider when selecting treatment.


Q: Is Ferraton considered a long-term or short-term treatment?

Treatment with Ferraton is generally for a prolonged period, and not short-term. Official guidelines indicate that the course often continues for three to six months after the patient's hemoglobin levels return to normal. This extended duration is required to ensure the body's iron stores are adequately replenished. Use beyond six months is generally managed under the supervision of a healthcare provider.


Q: Do Ferraton side effects go away after a while?

Gastrointestinal side effects, which are common, are often reported to be more frequent when a person first starts treatment or when the dose is increased. Clinical observations documented in medical literature suggest that patient tolerance to the iron dose has been observed to gradually improve in some patients after the initial one or two months.


Q: Is it safe to drink coffee or tea while using Ferraton?

Regulatory documents strongly recommend avoiding coffee, tea, and milk around the time you take your medicine. These substances can inhibit or block the iron from being absorbed properly by the body. Official documentation specifies that a separation of at least two hours from these drinks is necessary to prevent reduced absorption.


Q: Is Ferraton safe to use during pregnancy? (Informational only)

Official information indicates that the use of Ferraton is generally permitted during pregnancy and breastfeeding when a clinical diagnosis of iron deficiency has been established. Although small amounts may pass into breast milk, this is officially considered unlikely to cause harm to the baby.


Q: What does the term 'contraindication' mean for Ferraton?

A contraindication is a formal statement in the official drug label that the medicine is officially prohibited from use under specific conditions or by certain patient populations due to the risk of harm. For Ferraton, contraindications focus on prohibiting its use in people with conditions that cause excessive iron storage (like hemochromatosis).


Q: Is Ferraton a branded drug or a generic equivalent?

Ferraton contains the active ingredient Ferrous Fumarate, which is a widely used iron salt. This compound is available both under various brand names as well as in its generic (non-branded) formulation.


Q: Is Ferraton known to interact with blood pressure medications?

Official drug-interaction tables indicate that Ferraton is documented to reduce the absorption of certain co-administered drugs. This includes methyldopa (an agent used for blood pressure) and levothyroxine (thyroid hormone). Separation of dosing time is required to mitigate this reduced bioavailability.


Q: Do I need to take Ferraton with food, based on official information?

Official product information describes that the medicine is ideally taken on an empty stomach to optimize iron absorption. However, official information also notes that it may be taken with or immediately after food to help reduce common gastrointestinal side effects like nausea or stomach discomfort.


Q: Is it normal to feel a bit nauseous when first starting Ferraton?

Yes, nausea is listed as a common adverse reaction in regulatory documents for Ferraton. These common gastrointestinal side effects are often reported to be more frequent when starting treatment or when a dosage increase occurs.


Q: Why do some people stop taking Ferraton?

Treatment is typically stopped after three to six months once the body’s iron stores have been replenished and the primary goal is met. The most common reason cited in official literature for poor patient compliance leading to early discontinuation is the occurrence of frequent gastrointestinal side effects.


Q: Does Ferraton have a warning about driving or operating machinery?

Official patient information for oral ferrous iron products states that this medicine does not affect the ability to drive a car or operate machinery. No special restrictions are documented regarding these activities.


Q: Are there any long-term safety studies on Ferraton?

Research indicates that long-term effects are not fully established regarding the sustained maintenance of iron levels after treatment is stopped. Long-term use beyond six months is generally managed under the direction of a healthcare provider, and regulatory guidance recommends regular monitoring of iron levels.


Q: Is Ferraton a stimulant or a sedative?

Ferraton is classified in regulatory documents as an antianemic agent and an essential mineral supplement. It is not classified as a stimulant (a drug that increases activity) or a sedative (a drug that causes sleepiness or calming).


Q: What is the recommended duration of treatment with Ferraton?

The precise duration is established by a healthcare provider based on the patient's monitored iron status. Treatment typically continues for three to six months after the patient's hemoglobin has normalized to ensure that the body’s iron stores are fully refilled.


Q: Are there different strengths or forms of Ferraton available?

Yes, Ferraton (Ferrous Fumarate) is available in several forms, including oral tablets, capsules, or liquid solutions. Official sources indicate that available tablet strengths, for example, often include 210 mg and 325 mg formulations of Ferrous Fumarate.


Q: Does Ferraton have any Black Box Warnings mentioned by the FDA?

The FDA requires a prominent warning that accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under six years. This is the highest level of warning regarding the severe risk of accidental iron toxicity.


Q: What are the main risks associated with taking Ferraton?

The main risks listed in official safety documents are the potential for Acute Iron Poisoning (Toxicity), especially in young children from accidental overdose, and the risk of iron overload in patients with pre-existing iron storage diseases like hemochromatosis.


Q: Is Ferraton known to cause issues with liver or kidney function?

While not listed as a common side effect, some regulatory documents advise caution in elderly patients due to potentially decreased hepatic (liver) or renal (kidney) function. For long-term use, the regular monitoring of liver function indicators is recommended to ensure safety.

How should Ferraton be stored and disposed of?

How to Store and Dispose of Ferraton (Ferrous Fumarate)

The storage and disposal of Ferraton are strictly defined by regulatory labeling to maintain stability and ensure safety.

Storage Requirements

Ferraton must be stored at controlled room temperature, typically below 25°C (77°F), and protected from light and moisture. Keep the medicine in its original package with the container tightly closed and do not use it past the Expiry Date.

Child-Safety Storage

Keep this product out of the sight and reach of children. The label includes a mandatory warning that iron-containing products can cause fatal poisoning in children from accidental overdose.

Disposal Instructions

Do not dispose of unused or expired Ferraton by flushing it down the toilet or throwing it into general household waste. Instead, the product must be discarded in accordance with local requirements, such as through an authorized drug take-back program or by consulting a pharmacist.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ferraton found in:

A-Z Index: